Floatz logo

Saroglitazar

Nonalcoholic Steatohepatitis

Zydus Therapeutics Inc.Small moleculePhase 2Active
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
89/ 100

Competitive context

130 Active assets in the Nonalcoholic Steatohepatitis cohort.

Asset / SponsorPhaseRating
Resmetirom
City University of New York
Phase 4BBB
Pentoxifylline
Al-Azhar University
Phase 4BBB
Semaglutide
Cascade Pharmaceuticals, Inc
Phase 4BBB
Pioglitazone
Badr University
Phase 4BBB
Firsocostat
Gilead Sciences
Phase 2BBB

View all 50 →

Same molecule, other indications

Saroglitazar is also rated in:

primary biliary cholangitisDormant
BB
Indicative ·
71 / 100
View asset →
metabolic dysfunction-associated steatotic liver diseaseDormant
BB
Indicative ·
70 / 100
View asset →
inherited lipid metabolism disorderDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →